Articles tagged with Hiv Vaccines
The National Institute of Allergy and Infectious Diseases has awarded 14 grants totaling $7.8 million to focus on basic research for designing a safe and effective HIV vaccine. Recent discoveries about HIV biology are guiding the development of new vaccine strategies.
A multifaceted global effort could lead to an AIDS-free generation by expanding testing, treatment, and prevention programs. Combination antiretroviral therapy has significantly improved health and longevity for individuals infected with HIV, saving an estimated 700,000 lives globally in 2010.
Duke University has been awarded a seven-year, $186 million grant to develop an HIV vaccine by inducing precise immune factors. The program will focus on designing immunogens capable of preventing HIV transmission and protecting people worldwide.
Male study participants who received an experimental HIV vaccine were at higher risk of infection due to neutralizing antibodies to Ad5 or being uncircumcised. However, the risk level decreased over time and was equal to that of volunteers who received a placebo after about 18 months.
Laboratory studies of the RV144 vaccine have found that antibodies specific to a particular region of the HIV outer coat correlate with lower infection rates among vaccinated individuals. In contrast, high levels of a different type of envelope binding antibody appear to offer less protection against HIV.
Researchers analyzed immune responses in RV144 trial participants and found that antibodies specific to the V1V2 region correlated with lower infection rates. Vaccine recipients with high levels of IgA envelope protein binding antibody had less protection from HIV than those with low levels.
A study analyzing blood samples from RV144 trial participants found that those with high levels of a certain antibody were less likely to get infected. Researchers believe this may indicate the need for a different type of immune response in an HIV vaccine, but further testing is needed.
Researchers at Simon Fraser University have received a $2.7 million funding boost to enhance the effectiveness of their DNA-based HIV/AIDS vaccine. The team aims to strengthen a vaccine targeting the MPER region, a highly prized site for antibody production.
Scientists at Emory University and GeoVax Labs developed a vaccine that protected nonhuman primates against multiple SIV exposures over three years. The vaccine regimen included a DNA prime vaccine with GM-CSF, which enhanced immune responses and provided 70-84% overall protection.
Researchers have developed a new therapeutic vaccine that uses a person's own dendritic cells to stimulate an improved immune response against HIV. The vaccine showed virtually no side effects and significantly enhanced the body's ability to suppress the virus, but did not eliminate it entirely.
Researchers have developed a vaccine that partially protects monkeys against a virulent HIV-like virus, with the best predictor of protection being antibodies targeting the virus surface protein. The study suggests that an immune system mechanism for prevention differs from control of viral replication.
A recent study published in Nature shows that a novel combination of HIV vaccine candidates provides partial protection against Simian Immunodeficiency Virus (SIV) infection in rhesus monkeys. The optimal vaccine combinations also substantially reduced the amount of virus in the blood.
Researchers found that individuals with high numbers of Ad5-reactive T cells generated a weaker immune response to HIV vaccines. This finding may impact the efficacy of future vaccines using adenoviruses other than Ad5.
Researchers have identified a potential obstacle to developing an effective HIV vaccine: individuals with large numbers of immune cells responsive to the adenovirus used in the vaccine. Additionally, studies have found that obesity is associated with neuronal injury in the brain area crucial for body weight control and may inhibit nerv...
The SAV001 vaccine, developed by Dr. Chil-Yong Kang's team, has shown strong immune responses in preliminary tests with no adverse effects. It is the only HIV vaccine under development in Canada and one of few globally.
Researchers reveal how a broadly neutralizing HIV antibody called PG9 disarms the virus by grabbing hold of a sugar at residue 160, along with part of a second sugar and a string of amino acid residues in the V1/V2 region. This discovery may help scientists develop more effective HIV vaccines.
Researchers have discovered a highly effective antibody that can neutralize approximately 70% of globally circulating HIV strains by targeting the virus's envelope protein. The new findings suggest a promising target for AIDS vaccine development, with potential implications for broadening the protection against the fast-mutating virus.
The MVA-B vaccine has been shown to induce an 90% immune response in humans against Human's immunodeficiency virus (HIV), with 85% of volunteers maintaining this response for at least one year. The vaccine works by training the immune system to recognize and respond to HIV particles and infected cells.
Scientists are working on structure-based HIV vaccines and understanding the evolutionary processes of human B cells producing broadly neutralizing antibodies. New research tools and a better understanding of the human immune response offer optimism for developing an effective HIV vaccine.
A new University of Toronto study highlights the need for improved communication with high-risk communities about HIV vaccine trials. Researchers found that misinformation, distrust, and misunderstanding persist, affecting participants' willingness to participate.
Researchers have isolated 17 novel antibodies capable of neutralizing a broad spectrum of HIV variants, offering new targets for vaccine candidates. The potency of these antibodies is significantly higher than previously discovered ones, with some blocking infection up to 100 times more effectively.
A NIH-led team has discovered a method to guide the evolution of powerful HIV-neutralizing antibodies, which could lead to the development of an effective vaccine. The researchers used deep sequencing and bioinformatics techniques to decipher the genetic data of immune cells that produce these antibodies.
Researchers call for integrated strategies to prevent HIV infection, building on progress in vaccine research and the development of a vaginal gel. A combination of biomedical and non-biomedical approaches is seen as crucial to address the evolving landscape of HIV prevention.
Researchers at Oregon Health & Science University have developed a vaccine candidate that programs the immune system to respond swiftly to HIV, with over half of monkeys showing control over virus replication. The vaccine candidate has been shown to maintain control for over a year, outperforming antiretroviral therapy in clearing the ...
Researchers found that HIV evolves to evade ADCC antibodies, but these antibodies can force the virus to become weaker. This study suggests that inducing ADCC responses through a vaccine could help prevent HIV infection.
Scientists administered SIV vaccine to monkeys and found neutralizing antibodies and genetic factors correlated with protection. The vaccine reduced infection rate by 50% in some monkeys, providing evidence for immune response needed to prevent HIV infection.
Adaptive clinical trial designs may accelerate HIV vaccine development by rapidly screening out poor candidates and evaluating promising ones. These designs can provide key information on the immunological basis for HIV prevention, helping to advance vaccines through clinical trials more quickly.
Researchers discovered that HIV envelope protein complex can be exposed to raise more broadly cross-reactive antibodies against HIV. This finding could lead to the development of effective vaccines against HIV and AIDS.
A vaccine that induces antibodies in vaginal tissue is sufficient to protect monkeys from HIV exposure, challenging traditional blood-based immunity approaches. The study found mucosal antibodies can block viral entry without neutralizing effects in the bloodstream.
A new therapeutic vaccine has shown a significant response in the majority of AIDS patients, with a decrease in viral load. The vaccine, developed by the Hospital Clinic of Barcelona-IDIBAPS, uses patient's own dendritic cells and has achieved an improvement over previous initiatives.
A consortium of researchers has designed an early phase safety trial to assess mosaic vaccines in humans. The trial aims to test the mosaic concept and potentially lead to the next generation of HIV vaccine candidates.
A Phase I study has begun to evaluate a combination DNA prime/MVA vector boost vaccine regimen to protect against diverse subtypes of HIV-1. The study will enroll 92 participants and test two intramuscular delivery methods for the DNA prime, Biojector 2000 and CELLECTRA EP, to compare their effects on immune response.
Researchers will investigate biological mechanisms of broadly neutralizing antibody generation and its relevance to AIDS vaccine design. The U19 grant will support studies using samples from HIV-positive volunteers worldwide.
The formation of AVAN, the AIDS Vaccine for Asia Network, aims to accelerate research and development of an AIDS vaccine through government advocacy and improved coordination. With over 5 million people infected and 500 million at risk, regional efforts must be strengthened to combat HIV in Asia.
A new hepatitis E vaccine has demonstrated 100% efficacy in preventing infection, with protection offered across all age and sex subgroups. The vaccine is safe and can be used in both rich and poor countries, as well as for tourists, making it a crucial development in outbreak control.
Dr. Fauci presents new insights on the early pathogenic events following sexual exposure to HIV, informing strategies for prevention and vaccination. He focuses on the role of α4β7 in enhancing HIV binding to CD4+ T cells, a potential target for vaccine development.
Researchers found that HIV vaccines can induce protective antibody responses, but these responses can also lead to false-positive test results. A study of over 2,000 trial participants revealed that 41.7% developed reactive results in routine antibody detection methods.
A new review of existing literature found that several factors influence willingness to receive an HIV vaccine, including misconceptions about vaccine efficacy and fear of side effects. To ensure a future HIV vaccine is acceptable, public education is crucial to address these concerns.
Researchers have found two human antibodies, VRC01 and VRC02, that can neutralize over 90% of known HIV strains. These antibodies could be used to design improved HIV vaccines or developed as a therapy for HIV infection. The discovery was made using a novel molecular device that targets specific cells making antibodies against HIV.
Researchers at Scripps Research Institute have determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus (HIV). The study advances the effort to develop an AIDS vaccine by providing insights into how broadly neutralizing antibodies work.
Researchers found that vaccinia immunization reduces HIV replication, suggesting it could provide protection against subsequent infection. The decline of smallpox vaccination in the mid-20th century may have led to a loss of this protection, contributing to HIV's rapid contemporary spread.
Novel vaccines targeting immune cells in the gut may improve patient compliance and vaccination rates, especially in developing countries. Powder-based vaccinations also show promise, with stable dry powder formulations stabilizing the TB vaccine.
Researchers at Duke University Medical Center have discovered a set of naturally occurring antibodies that can block HIV's entry into certain blood cells. These polyreactive anti-phospholipid antibodies show promise as a potential new strategy for HIV vaccine design.
Researchers at Universite de Montreal and VGTI have discovered a new mechanism by which HIV infects immune cells, characterizing the role of two molecules PD-1 and IL-10 in this process. The study suggests that blocking these interactions may restore the immune response in HIV-infected patients.
A pneumococcal conjugate vaccine has been shown to prevent 74% of recurrent cases of pneumonia and meningitis in HIV-infected adults in Africa. The vaccine was particularly effective in patients with low CD4 counts, a group previously considered ineligible for vaccination.
A new HIV vaccine strategy, called 'mosaic vaccines,' has shown promise in expanding immune responses in rhesus monkeys. The approach uses computational methods to create small sets of highly variable artificial viral proteins that stimulate a strong immune response against the diverse forms of HIV.
Scientists have revealed the 3-D structure of vesicular stomatitis virus (VSV), a model system for understanding negative-strand RNA viruses. The research provides insights into the assembly process and proposes a model for viral structure, potentially leading to advances in cancer treatment and HIV vaccines.
A new vaccine against tuberculosis has been shown to be effective in preventing the disease in people with HIV infection. The DarDar Health Study found that the Mycobacterium vaccae (MV) vaccine reduced the rate of definite tuberculosis by 39 percent among 2,000 HIV-infected patients in Tanzania.
Scientists at Thomas Jefferson University developed a promising AIDS vaccine using a rabies virus-based strategy, inducing neutralizing antibodies and CD8+ T cell responses in monkeys. The study showed that the vaccine protected against disease and elicited significant antibody activity against SIV.
A new study found that a moderate level of acceptability for an HIV vaccine exists, but high-risk communities may not automatically accept it. The key factors influencing acceptance are efficacy, side effects, and cost. Education is also crucial to ensure the public trusts the vaccine.
Scientists have identified a key mechanism behind the binding action of HIV antibodies 2F5 and 4E10, which could lead to the development of more effective vaccines. The study found that successful docking requires attachment to the virus's membrane containing lipid.
A US-led clinical trial in Thailand has found that an investigational vaccine regimen reduced the risk of HIV infection by 31% among vaccinated participants. The study, which enrolled over 16,000 adults, suggests a promising approach to preventing HIV transmission.
Researchers at UC Santa Cruz are working on a new approach to AIDS vaccine development using novel HIV protein structures and broadly neutralizing antibodies to combat the virus' high variability. The $3.5 million NIH grant will support studies exploring these promising findings and potentially lead to more effective vaccines.
Two new broadly neutralizing antibodies (bNAbs) have been discovered to target the HIV virus, providing a promising lead for AIDS vaccine development. The newly found antibodies, PG9 and PG16, attach to a novel site on the virus, making them more accessible for vaccine design.
Researchers have identified two powerful new antibodies to HIV that reveal a potential Achilles heel on the virus. The discovery offers new avenues for designing an effective AIDS vaccine and may lead to the identification of additional vulnerabilities in the virus.
Researchers at Yerkes National Primate Research Center propose alternative approaches to developing an effective AIDS vaccine, including making infected individuals resistant to disease progression or reducing the number of cells the virus can infect. They draw inspiration from African nonhuman primates that adapt to HIV-like viruses i...
A new study found that college students with high danger invulnerability tend to decline HIV vaccines, while those with psychological invulnerability are more likely to accept them. The study suggests that efforts to promote vaccine acceptance should consider the role of invulnerability in students' health-protective behaviors.
Researchers will test the AERAS-402/Crucell Ad35 vaccine candidate in people living with HIV, aiming to induce critical CD8 immune cells. The study is crucial for developing an effective TB vaccine, especially for those with HIV, who are 20 times more likely to develop TB.
Researchers at The Wistar Institute have defined a key target of an evolutionarily conserved protein that regulates the process of aging. Deacetylation of histone H4K16 by Sir2 maintains telomere stability, crucial for yeast cells to replicate and live longer.
A novel vaccine approach may have broken the impasse in developing an effective HIV vaccine by bypassing the usual path followed by vaccine developers. The technique, which uses gene transfer technology, protected monkeys from SIV infection and produced long-lived neutralizing activity.